🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Iovance Biotherapeutics clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA and UK registers with Iovance Biotherapeutics as lead sponsor. Synced 26 Sep 2026
8Current trials
5Recruiting now
2Drugs in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Iovance Biotherapeutics is the lead sponsor of 8 current clinical trials in our USA and UK registers. 5 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Lifileucel and Pembrolizumab. The most-studied condition is Unresectable Melanoma.

ClinicalTrials.gov trials by status

  • Recruiting563%
  • Not yet open113%
  • Active, closed225%

Trials by phase

  • Phase 2338%
  • Phase 1/2338%
  • Phase 3113%
  • Phase 1113%
01

Clinical trials sponsored by Iovance Biotherapeutics

8 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
NCT04614103 · ClinicalTrials.gov ↗ · Metastatic Non Small Cell Lung Cancer
Phase 2 Recruiting 2021-05 UK, USA
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
NCT05727904 · ClinicalTrials.gov ↗ · Metastatic Melanoma, Unresectable Melanoma, Melanoma
Phase 3 Recruiting 2023-03 UK, USA
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
NCT05361174 · ClinicalTrials.gov ↗ · Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer
Phase 1/2 Recruiting 2022-07 USA
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
NCT06481592 · ClinicalTrials.gov ↗ · Endometrial Cancer
Phase 2 Recruiting 2024-10 USA
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
NCT06940739 · ClinicalTrials.gov ↗ · Unresectable Melanoma, Metastatic Melanoma, Ocular Melanoma
Phase 1/2 Recruiting 2025-03 USA
A Study of IOV-5001 in Adults With Advanced Solid Tumors
NCT07743723 · ClinicalTrials.gov ↗ · Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC)
Phase 1/2 Not yet open 2026-09 USA
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
NCT07288203 · ClinicalTrials.gov ↗ · Melanoma (Skin Cancer), Unresectable Melanoma, Metastatic Melanoma
Phase 2 Active, closed 2025-11 UK, USA
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
NCT06566092 · ClinicalTrials.gov ↗ · Soft Tissue Sarcoma, Primary Central Nervous System Carcinoma, Melanoma
Phase 1 Active, closed 2024-03 USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Iovance Biotherapeutics trials

2 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Iovance Biotherapeutics trials

16 conditions
Unresectable Melanoma4Metastatic Melanoma4Melanoma2Melanoma (Skin Cancer)1Metastatic Non Small Cell Lung Cancer1Stage III Non-small Cell Lung Cancer1Stage IV Non-small Cell Lung Cancer1Endometrial Cancer1Soft Tissue Sarcoma1Primary Central Nervous System Carcinoma1Rhabdomyosarcoma1Ocular Melanoma1Advanced Solid Tumors1Non-Small Cell Lung Cancer1Triple Negative Breast Cancer (TNBC)1Colorectal Cancer1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA85
Clinical trials in UK32

A trial with sites in more than one country appears in each of those registers.

05

Questions about Iovance Biotherapeutics trials

How many clinical trials does Iovance Biotherapeutics sponsor?

Iovance Biotherapeutics is the lead sponsor of 8 current trials on ClinicalTrials.gov in our USA and UK registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Iovance Biotherapeutics trials recruiting?

Yes. 5 of its 8 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Iovance Biotherapeutics testing?

Its current trials name 2 drugs and biologicals as interventions. The most frequent are Lifileucel (3) and Pembrolizumab (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.